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Abstract: During the prostate cancer (PCa) development and its progression into hormone independency, androgen receptor 
(AR) signals play a central role by triggering the regulation of target genes, including prostate-specific antigen. However, 
the regulation of these AR-mediated target genes is not fully understood. We have previously demonstrated a unique role 
of HOXB13 homeodomain protein as an AR repressor. Expression of HOXB13 was highly restricted to the prostate and its 
suppression dramatically increased hormone-activated AR transactivation, suggesting that prostate-specific HOXB13 was a 
highly potent transcriptional regulator. In this report, we demonstrated the action mechanism of HOXB13 as an AR repressor. 
HOXB13 suppressed androgen-stimulated AR activity by interacting with AR. HOXB13 did neither bind to AR responsive 
elements nor disturb nuclear translocation of AR in response to androgen. In PCa specimen, we also observed mutual 
expression pattern of HOXB13 and AR. These results suggest that HOXB13 not only serve as a DNA-bound transcription factor 
but play an important role as an AR-interacting repressor to modulate hormone-activated androgen receptor signals. Further 
extensive studies will uncover a novel mechanism for regulating AR-signaling pathway to lead to expose new role of HOXB13 
as a non-DNA-binding transcriptional repressor. 
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a homodimer to the cognate DNA response elements on the 
promoter, where it interacts with other transcriptional factors 
and activates downstream gene transcription. AR has distinct 
functional domains, a highly conserved DNA binding domain 
comprising two zinc finger motifs, a C-terminal ligand 
binding domain, and a poorly conserved amino-terminal 
domain that may contain transcriptional activation domains. 
AR can enhance or inhibit transcription by recruiting many 
co-regulators to the hormone-receptor complex. Moreover, 
it is believed that AR-mediated pathway plays a central role 
during androgen-independent progression of prostate cancer 
(PCa) cells. However, the regulation of these AR-mediated 
target genes under both hormone-dependent and -free 
environment is not fully understood. 
Introduction
Androgen receptor (AR) has a key regulatory function 
in the growth and differentiation of normal and cancerous 
prostate epithelial cells by triggering the regulation of target 
genes such as jun, fos, myc, cdks, and fibroblast growth 
factor. Transactivation of AR is initiated upon binding to 
androgen. AR then translocates into the nucleus and binds as Link between HOXB13 and androgen receptor
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Hox homeobox genes is generally considered as 
transcription factors that function during development 
to regulate axial regional specification during embryonic 
development and are expressed with temporal and spatial 
colineality. Despite intensive research, the mechanism of 
action of Hox proteins still remains unclear. Due to the 
presence of the DNA-binding homeodomain, a paradigm that 
the Hox proteins function as transcription factors was quickly 
established (Levine & Hoey, 1988). However, large numbers 
of Hox proteins alone do not bind to target DNA with high 
affinity or specificity (Shen et al., 1996), but require other 
cofactors to form cooperative DNA binding complexes, such 
as Pbx/Exd and /Meis/Prep/Htx (Mann & Chan, 1996). Pbx 
proteins physically interact with the YPWM motif of the Hox 
proteins, increasing their DNA binding affinity and defining 
their sequence specificity. However, Abd-B subfamily Hox 
proteins, including HOXB13, do not have a typical YPWM 
motif and consequently do not interact with Pbx/Exd. A few 
HOX target genes were described without cooperative DNA 
binding with partner proteins (Chariot et al., 1999; Raman et 
al., 2000a; Raman et al., 2000b). These proteins, comprising 
paralog groups 9-13, bind to DNA in the absence of cofactor 
proteins (Shen et al., 1997). The mechanism of transcriptional 
regulation by Abd-B hox proteins remains poorly understood. 
HOX proteins are also involved in the regulation of 
coactivator function without DNA binding. Shen et al. 
reported that most HOX proteins, including the HOX-
13 paralog, bind to CBP/p300 coactivators through their 
homeodomain (Shen et al., 2001; Shen et al., 2004). CBP/
p300 does not form DNA binding complexes with the 
HOX proteins but instead prevents their binding to DNA, 
suppressing the HOX proteins’ transactivating function. 
Conversely, HOX proteins inhibit the activity of CBP, 
suggesting that HOX proteins may inhibit CBP histone 
acetyltransferase activity and thus function as repressors of 
gene transcription. These lines of evidence suggest that HOX 
proteins function through a variety of pathways.
Due to the highly prostate-specific and AR-correlated 
expression pattern of HOXB13, we extensively studied the 
role of HOXB13 homeodomain protein in the regulation of 
AR-mediated signaling pathway (Jung et al., 2004a and b). 
Briefly, HOXB13 significantly suppressed androgen-activated 
AR transcriptional activity in a dose responsive manner while 
HOXB13 generally promoted the activity of other promoters, 
including RSV, SV40, and hormone-activated estrogen 
receptor. HOXB13 further down-regulated the expression of 
AR target proteins, including prostate specific antigen (PSA) 
and physically interacted with exogenous AR. Suppression 
of endogenous HOXB13 greatly promoted hormone-
activated AR activity (up to 3 fold), suggesting that low level 
endogenous HOXB13 is very potent in the regulation of AR 
activity. Consequently, HOXB13 suppresses the growth of 
AR-expressing PCa cells, which can be counteracted by the 
addition of hormone-activated AR. These results suggest 
that HOXB13 functions as an AR modulator by specifically 
regulating this powerful growth signals. Since HOXB13 
expression seems to be restricted in AR-expressing prostate 
cells in that study, balance of HOXB13 and AR may be 
important for cells to avoid abnormal proliferation. At the 
same time, loss of HOXB13 may be required for androgen-
independent PCa cells to survive. 
The objective of this report is to investigate the mechanistic 
involvement of HOXB13 in the regulation of AR-signaling. 
We tested to determine whether HOXB13 requires DNA-
bound AR to inhibit AR activity. We also tested whether 
HOXB13 physically interacted with AR and this type of 
association resulted in disturbance of nuclear translocation of 
AR. 
Materials and Methods
Plasmids and reagents
The pFLAG-HOXB13, pAd-GFP-HOXB13, and pGL-
ARE4-Luc have been previously described (Jung et al., 2004a). 
The pPSA-luc contains the entire PSA promoter as previously 
described (Lee et al., 2002). Anti-AR antibodies were from 
Santa Cruz Biotechnology. Anti-HOXB13 antibodies were 
custom-made as previously described (Kim et al., 2010). 
Synthetic testosterone, R1881, was from NEN Life Science 
and used at a final concentration of 10 nM. Charcoal dextran-
treated (CDT) fetal bovine serum (FBS) was from Invitrogen. 
Cell culture
Human prostate cancer cell LNCaP was routinely cultured 
in RPMI media (Invitrogen) supplemented with 5% FBS at 
37
oC in an atmosphere containing 5% CO2. All cultures were 
fed with fresh medium every 3-4 days. 
Transient transfections
Approximately 1×10
5 cells were plated in a 24-well plate 
16 hours before transfection. To see the hormone effect, Anat Cell Biol 43:284~293, 2010 Sin Do Kim, et al 286
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cells were grown under 5% CDT-FBS for three days before 
the transfection. The transfections were carried out using 
the Lipofectamine 2000 (Invitrogen) with 0.1 μg of reporter, 
0.1 μg of test plasmid, and 2 ng renilla as described by the 
manufacturer’s protocol. Six hours after transfection, the cells 
were washed and fed with medium containing 5% CDT-FBS. 
The cells were treated with either R1881 synthetic androgen or 
ethanol. After 36 hours, the cells were washed with PBS, lysed 
with 100 μl of passive lysis buffer, and assayed for luciferase 
activity as relative light units using the Dual Luciferase 
assay system (Promega). The transfection experiments 
were performed in triplicate and the results are reported as 
the mean ± S.D. The relative luciferase activity (RLU) was 
measured. All statistical tests were two-sided, and P values 
less than .01 were considered to be statistically significant.
DNA microarray analysis
LNCaP cells were infected with either Ad-GFP or Ad-
GFP-HOXB13 at a multiplicity of infection (MOI) of 2 under 
the influence of androgen. Infectivity and cell viability were 
carefully monitored by fluorescence microscopy for 36 hours. 
Total RNA was purified using Qiagen RNeasy system. Quality 
control of RNA was made by both spectrophotometry and 
agarose gel separation of ribosomal RNA. Gene chip analysis 
was done on contractual basis with Indiana University 
Center for Medical Genomics (Indinapolis, Indiana, USA). 
Affymatrix GeneChip
® Human Genome U133 was used 
and hybridization were performed in triplicate for each 
sample. Arrays were then scanned using scanner, controlled 
by Affymetrix GCOS software. Images were examined for 
defects. The Affymetrix
® Microarray Suite version 5.2 (MAS5) 
algorithm analyzed the hybridization intensity data from 
GeneChip
® expression probe arrays and calculated a set of 
metrics that described probe set performance. The average 
intensity on each array was normalized by global scaling to a 
target intensity of 1000. 
Electrophoretic mobility shift assay
Oligos (Integrated DNA Technologies) were annealed by 
heating up to 95°C for 10 min and slowly cooling down to 
room temperature in TEN buffer (10 mM Tris-HCl, pH 8.0, 
1 mM EDTA, 0.1 M NaCl). An androgen response element 
(ARE) was derived from MMTV and double-stranded 
oligonucleotides, tgtacaggatgttct, were end-labeled with 
(
32P-γ-) ATP using T4 polynucleotide kinase (New England 
Biolabs, Beverly, MA). Either nuclear extracts (2 μg) or GST-
purified proteins (1 or 5 μg) were prepared as previously 
described.  Labeled probe (10,000 cpm) and proteins were 
incubated with binding buffer containing 20 mM HEPES 
(pH 7.6), 10 mM (NH4)2SO4NaCl, 1 mM EDTA, 1 mM 
dithiothreitol, 30 mM KCl and 3 μg poly(dI-dC) (Sigma) at 
25
oC for 30 min.  Samples were subjected to electrophoresis at 
room temperate using 6% nondenaturing polyacrylamide gel 
in 0.5% TBE at 32 mA for 4 h.  For competition experiments, 
800X more unlabeled oligos were incubated with nuclear 
extracts for 30 min at 25
oC prior to the addition of the labeled 
probe. 
Coimmunoprecipitation assay
LNCaP cells were grown under 5% CDT-FBS for 3 days. 
A 10 nM final concentration of R1881 or ethanol was added. 
Nuclear extracts were collected as previously described (Lee 
et al., 2003). Nuclear extracts (100 μg) were preincubated with 
4 μg of anti-HOXB13 antibodies for 3 hours at 4
oC, followed 
by adding protein A/G agarose (Santa Cruz Biotechnology). 
Immunoprecipitates obtained by centrifugation were washed 
with tris-buffered saline three times and eluted with 2X 
SDS loading buffer. Proteins were separated on 10% SDS-
PAGE using the Novex electroporation system (Invitrogen). 
After proteins were transferred to PVDF membrane, 
immunoblotting was followed by using anti-AR antibodies 
primary antibodies, followed by incubation with horseradish 
peroxidase-conjugated secondary antibodies. Blots were 
developed by the ECL detection system (Pierce).
Confocal microscopy
LNCaP cells were plated onto 4-well chamber slides under 
5% CDT-FBS for 72 hours. Then, cells were given by either 
R1881 at 10 nM final concentration  or ethanol. Cells were 
briefly risensd by PBS and fixed with 2% paraformaldehyde 
at room temperature for 10 minutes. Cells were preincubated 
with 3% normal goat serum followed by incubation with both 
anti-HOXB13 and anti-AR antibodies. After rinsing with 
PBS, cells were given by mixture of Alexa Fluor
® 488 anti-
mouse and 568 anti-rabbit antibodies (Invitrogen). After 
washing, slides were covered with anti-fade mounting agent 
and monitored with Zeiss LSM510 confocal microscopy.
Immunohistochemistry
The tissues were deparaffinized followed by microwave 
antigen retrieval in citrate buffer. Endogenous peroxidase 
activity was destroyed by treating tissue sections with 0.3% Link between HOXB13 and androgen receptor
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In order to identify the profiles of androgen-regulated 
genes affected by HOXB13, LNCaP cells were grown in 
charcoal dextran-treated (CDT)-FBS condition for 3 days. 
Either adenoviral recombinant HOXB13 or control virus was 
given to the cells followed by the addition of R1881 synthetic 
androgen for 36 hours. Purified RNA was analyzed by Gene 
Chip analysis. Out of 401 known and unknown potential 
HOXB13 target genes, there were 26 androgen-stimulatory 
genes and 4 androgen-inhibitory genes (Table 1). All of 
androgen-regulated gene expressions were counteracted by 
HOXB13. HOXB13 regulated the expression of most AR 
responsive genes, including NKX3.1, prostate-specific antigen, 
PDEF, and serpinI1.
HOXB13 physically interacts with AR but not binds 
to DNA
Since HOX proteins are generally known as transcription 
factors with intrinsic DNA-binding ability due to the presence 
of a highly conserved homeodomain, we tested whether 
HOXB13 binds to the androgen responsive element (ARE) to 
modulate AR transcriptional activity. A gel mobility assay was 
employed. AR binding to ARE was used as a positive control 
due to the lack of information on HOXB13-binding DNA 
sequences. As shown in Fig. 2A, endogenous AR from LNCaP 
cells binds to 
32P-labeled ARE (lane 1), whose signal was 
abolished by the addition of unlabeled ARE (lane 2). However, 
GST-HOXB13 (1~5 μg) did not bind to ARE (lanes 4-5). 
We then studied the interaction between HOXB13 and AR 
by co-immunoprecipitation assay. LNCaP cells were grown 
H2O2 followed by avidine-biotin blocking. After nonspecific 
reactivity was sequentially blocked by an avidin-biotin 
blocking reagent and 10% normal serum, the tissues were 
incubated with antibodies against HOXB13, AR, PSA, or 
transcription factor IID. Tissues were then incubated with 
appropriate second antibodies conjugated with biotin.  
Then, the signals were amplified by the horseradish 
peroxidase-DAB detection method.
Results
HOXB13 is a repressor of androgen-stimulated AR 
transactivation
We have previously observed that HOXB13 exerted 
suppressive role in androgen-stimulated AR-mediated 
transactivation (Jung et al., 2004b). We first studied if there 
was any functional association between HOXB13 and AR 
using PSA promoter encompassing 6.1 kb of PSA promoter 
and enhancer region in LNCaP PCa cells. Transient trans-
fection combined with reporter transcription analysis was 
performed. Using pGL-PSA-luc, HOXB13 repressed about 
50% of androgen (R1881)-activated AR activity of PSA 
promoter while there was AR-stimulatory role in androgen-
independent activation of PSA (Fig. 1A). Using four copies 
of androgen response elements cloned into a pGL-TATA-luc 
vector, pGL-ARE4-luc, transfection of HOXB13 dramatically 
inhibited androgen-activated AR transcriptional activity (Fig. 
1B).
Fig. 1. HOXB13 is an androgen receptor repressor in presence of androgen. (A) LNCaP cells were transiently transfected with 100 ng of pPSA-
luc, 2 ng of renilla, and 100 ng of pFLAG-HOXB13 with or without 10 nM R1881, synthetic androgen. pFLAG-CMV was used as a counterpart 
of pFLAG-HOXB13. (B) similar to (A) except that pARE4-luc (100 ng) was used. Luciferase assays were performed 48 hours post-transfection. 
Values indicate as relative luciferase unit (RLU). Each bar represents the mean±S.D.Anat Cell Biol 43:284~293, 2010 Sin Do Kim, et al 288
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in the presence or absence of androgen. Nuclear extracts 
from cells were immunoprecipitated with anti-HOXB13 
antibodies followed by Western blot analysis. As shown in 
Fig. 2B, AR was detected by its antibodies, while no band was 
detected with immunoprecipitates using normal IgG. This 
physical interaction between HOXB13 and AR was occurred 
regardless of the presence of androgen. Since HOXB13 does 
not possess the LXXLL or FXXLF motif, common motifs in 
AR-interacting proteins, HOXB13-interacting domain of AR 
seems to be different from other steroid receptor coactivators. 
These results suggest that HOXB13-mediated suppression of 
AR activity is not due to the binding of HOXB13 to ARE, but 
by interaction with AR. 
Table 1. Alteration of androgen-regulated genes by forced expression of HOXB13 in LNCaP cell followed by DNA microarray analysis
Gene Fold change Accession number Description
Androgen-stimulatory
    genes
NKX3-1 －2.9291525 NM_006167 NK3 transcription factor related, locus 1
KLK2 －4.773123 NM_005551 Kallikrein 2, prostatic
KLK3 (PSA) －1.3592767 NM_145864 Kallikrein 3 (prostate specific antigen)
KLK4 －3.3004613 NM_004917 Kallikrein 4 (prostase)
KLK15 －2.5023859 NM_138564 Kallikrein 15
TMPRSS2 －3.1446557 NM_005656 Transmembrane protease, serine 2
TMEPAI －7.665736 NM_199171 Transmembrane, prostate androgen induced RNA
HES6 －5.6520233 NM_018645 Hairy and enhancer of split 6
ANKH －2.3815665 NM_054027 Ankylosis, progressive homolog
RAB4A －3.3872705 NM_004578 RAB4A, member RAS oncogene family
RAB4B －1.3151248 NM_016154 RAB4B, member RAS oncogene family
AZGP1 －2.7943566 NM_001185 Alpha-2-glycoprotein 1, zinc
ACTN1 －2.5256789 NM_001102 Actinin, alpha 1
FACL2 －2.3272305 NM_021122 Fatty-acid-Coenzyme A ligase, long-chain 2
CAMKK2 －2.5422819 NM_172226 Calcium/calmodulin-dependent protein kinase kinase 2, beta
NDRG1 －4.8543024 NM_006096 N-myc downstream regulated gene 1
KRT18 －4.0144486 NM_199187 Keratin 18
SORD －3.6557357 NM_003104 Sorbitol dehydrogenase
ADAMTS1 －7.6324997 NM_006988 Disintegrin-like and metalloprotease with thrombospondin type 1 motif 1
TPD52 －2.4240575 NM_005079 Tumor protein D52
DHCR24 －2.083525 NM_014762 24-dehydrocholesterol reductase
FKBP5 －5.590794 NM_004117 FK506 binding protein 5
MAF －3.238104 NM_005360 v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian)
SPDEF －12.381798 NM_012391 SAM pointed domain containing ets transcription factor
MYC －3.5553253 NM_002467 v-myc myelocytomatosis viral oncogene homolog
KLF4 －1.9423846 NM_004235 Kruppel-like factor 4 (gut)
Androgen-inhibitory
    genes
SERPINI1 17.762297 NM_005025 Serine (or cysteine) proteinase inhibitor (neuroserpin)
UGDH 1.218914 NM_003359 UDP-glucose dehydrogenase
ID2 5.32779 NM_002166 Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein
CDC14B 1.5039003 NM_033332 CDC14 cell division cycle 14 homolog BLink between HOXB13 and androgen receptor
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HOXB13 does not disturb nuclear translocation of 
AR upon exposure to androgen
In order to demonstrate that HOXB13-mediated AR 
suppression is due to the prevention of nuclear translocation 
of AR, we performed immuno  fluorescence assay in LNCaP 
cells which were grown in the absence or presence of 
androgen (Fig. 3). In the absence of synthetic androgen 
R1881, both HOXB13 and AR are generally distributed 
in both cytoplasmic and nuclear com  partments of cells. 
Upon stimulation of R1881, nuclear translocation of AR 
was observed while HOXB13’s cellular distribution was 
unchanged. These results suggest that HOXB13 did not 
disturb the nuclear translocation of AR. 
HOXB13 and AR were mutually expressed
Expression of HOXB13 is exclusively abundant in prostate 
(Sreenath et al., 1999; Hood et al., 2004; Jung et al., 2004b; 
Takahashi et al., 2004). Interestingly, expression of HOXB13 
was limited to AR-expressing PCa cells and expression 
between HOXB13 and AR was not mutually regulated 
(Jung et al., 2004b). Due to the notorious heterogeneous 
and multifocal nature of PCa, we have localized expression 
of HOXB13 in various grades of prostate tumors using 
immunohistochemistry. As shown in Fig. 4, serial sections 
Fig. 2. HOXB13 physically interacts with androgen receptor (AR), 
not with DNA, to suppress androgen-stimulated AR activity. (A) To 
see if HOXB13’s AR-suppressive function is due to DNA binding, 
electrophoretic mobility shift assay was performed. An androgen 
response element (ARE) was derived from MMTV and double-
stranded oligonucleotides, tgtacaggatgttct, were labeled and used as 
a probe. First, LNCaP cells were grown in the presence of androgen 
followed by nuclear extraction. GST-HOXB13 protein was produced 
and purified. LNCaP nuclear extracts were used as a positive control 
(lane 1), whose signals were abolished by the addition of cold ARE 
(800X) (lane 2). Either GST (lane 3) or GST-HOXB13 (1-5 μg) (lanes 
4-5) replaced nuclear extracts to see if HOXB13 binds to ARE. (B) For 
the in vivo interaction of HOXB13 and AR, co-immunoprecipitation 
was performed. LNCaP cells were grown under CDT-FBS for 3 
days and treated with or without androgen and nuclear extracts were 
collected 48 hours after treatment. One hundred μg of proteins were 
mixed with 4 μg of anti-HOXB13 antibodies, followed by conjugation 
to agarose A/G beads. Normal IgG was used as negative control. 
Precipitated fractions (IP) were resolved by SDS-PAGE and analyzed 
by Western blot using anti-AR antibodies.  Fig. 3. HOXB13 does not disturb nuclear translocation of androgen 
receptor (AR) in the presence of androgen. LNCaP cells were grown 
under CDT-FBS for three days before stimulated by R1881 or vehicle 
for 6 hours. Cells were then fixed and co-immunostained for HOXB13 
and AR and viewed by confocal microscopy. Nuclei were stained in 
blue using DAPI (a, e). AR (b, f) and HOXB13 (c, g) were stain in 
green and red, respectively. Merged images for AR and HOXB13 were 
shown in (d) and (h). The scale bars were 20 μm.Anat Cell Biol 43:284~293, 2010 Sin Do Kim, et al 290
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Fig. 4. Expression of HOXB13 and androgen 
receptor (AR) was mutually regulated in 
prostate tumors. Serial sections of prostate 
tissues were immunostained for HOXB13, AR, 
PSA, and TFID. Malignant tumors used in 
this study belong to combined Gleason score 9. 
While HOXB13 and AR were colocalized in 
some tumor cells, there also were HOXB13 and 
AR-negative tumor cells. Transcription factor 
IID (TFIID) was used as a positive control. 
Magnification, 10X.Link between HOXB13 and androgen receptor
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of benign prostate showed coexpressed phenomenon of 
HOXB13 and AR (upper row). High magni  fi  ca  tions of some 
selected tumors cells were shown in bracket to demonstrate 
immunoreactive HOXB1. PSA expression was accordingly 
observed as an AR target protein. Transcription factor IID 
was used to show protein integrity. Most tumor cells coexpress 
HOXB13, AR, and PSA (middle row) while some tumor 
cells express neither HOXB13 nor AR with minor expression 
of PSA (bottom row). Note that HOXB13 was mostly 
localized in highly invasive tumor cells, leading technical 
difficulty to test molphologically identical field (middle row). 
Nevertheless, these results suggest that regulation of HOXB13 
expression is tightly involved with the control of AR.
Discussion
HOXB13 developmental protein predominantly 
expresses in the prostate but its biological role is not clear 
in this hormone-dependant organ. We have previously 
demonstrated that HOXB13 was an AR modulator, which 
ultimately inhibited AR-mediated growth signaling under 
the control of androgen. In this report, HOXB13-induced 
suppression of AR activity was mainly mediated through 
physical interaction with AR. HOXB13 did not bind to ARE 
to compete binding site with AR. In addition, HOXB13 did 
not interfere nuclear transloation of AR in the presence of 
androgen. Taken together, a model of HOXB13’s role in 
the regulation of AR-mediated signaling is shown in Fig. 
5. Upon stimulation of androgen, HOXB13 exert as an AR 
repressor by direct or indirect binding to AR. Sequestration 
of coactivators from AR by excessive HOXB13 prevent 
proper formation of AR coactivators complex, resulting in 
suppression of AR target gene expression. At the same time, 
HOXB13 can simply recruit more corepressors to the AR 
complex to show suppressive effect. Interestingly, interaction 
between HOXB13 and AR is made regardless of the presence 
of androgen, suggesting that HOXB13 have an important 
role in androgen-independent progression of PCa. In fact, 
we recently reported that HOXB13 was highly overexpressed 
in the majority of hormone refractory PCa compared to 
hormone responsive PCa (Kim et al., 2010). Overexpressed 
HOXB13 in these malignant PCa provides either a positive 
growth signal or better survivability in an androgen-deprived 
harsh environment.
Hox-13 paralog is especially important to the development 
of male accessory sexual organs, including the prostate 
(Podlasek et al., 1997; Podlasek et al., 1999a; Podlasek et al., 
1999b). All Hox-13 genes except Hoxc13 are expressed in the 
prostate during embryonic development. However, Hoxa13 
and Hoxc13 are no longer expressed after the embryonic stage 
(Podlasek et al., 1999a; Prins et al., 2001). Hoxd13 and/or 
Hoxa13-deficient mice showed morphological abnormalities 
in male accessory sex organs including the seminal vesicle 
and prostate (Podlasek et al., 1997; Warot et al., 1997; 
Podlasek et al., 1999a). Hoxc13, the last identified vertebrate 
Hox gene, has been shown to be limitedly expressed in the 
caudal extent of the spinal cord, tail bud and urogenital sinus 
in an androgen-independent manner (Zeltser et al., 1996; 
Sreenath et al., 1999). Recently, mice homozygous for Hoxb13 
loss-of-function mutations showed overgrowth in all major 
structures derived from the tail bud (Economides et al., 2003) 
and malformation of ducts of the ventral prostate, including 
complete loss of secretory proteins (Economides & Capecchi, 
2003). The phenotype shown in Hoxb13 mutant mice was 
similar to Nkx3.1 mutant mice and developed into swollen 
prostate in older mutant mice. Some isoforms of CD44 
have been shown to be associated with tumor progression 
and metastasis including lung and gastric cancers (Lagorce-
Pages et al., 1998; Wimmel et al., 2001). The mis-expression 
of CD44 in luminal epithelial cells observed in these mice 
is consistent with pre-neoplastic lesions in many tissue 
types. The involvement of Hoxb13 in ventral prostate may 
provide protection to this tissue from neoplasia in Nkx3.1 
mutant mice since Nkx3.1 mutations do not cause prostatic 
intraepithelial neoplasias in the ventral prostate. However, 
Fig. 5. Model of HOXB13-mediated suppression of androgen-
activated androgen receptor (AR) signaling. Rather than inhibiting AR 
binding to its cognitive DNA, HOXB13 regulates formation of AR 
coactivators and/or corepressors.Anat Cell Biol 43:284~293, 2010 Sin Do Kim, et al 292
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there have been no studies on the biological function of 
HOXB13 in the tumorigenic process in human prostate. Due 
to its nature as a developmental gene showing a tissue-specific 
expression pattern, HOXB13 may be an important factor in 
aberrant prostate differentiation leading to tumorigenesis.
Our long term goal is to elucidate the function of HOXB13 
and its action of mechanism during the prostate tumor 
development and progression into hormone-refractory 
tumors. We believe that elucidating the exact role/mechanism 
of HOXB13 in the regulation of AR activity is an important 
task to better understand a dogma in the process of PCa 
development. This report at least partly tested the hypothesis 
that HOXB13 is a unique repressor to modulate hormone-
activated androgen receptor signals. This hypothesis is 
based on the following observations. First, unlike other AR 
cofactors, HOXB13 is exclusively expressed to the prostate 
and is a very potent AR repressor (Sreenath et al., 1999; Jung 
et al., 2004b; Takahashi et al., 2004; Edwards et al., 2005). 
Second, expression pattern of AR and HOXB13 is correlated, 
one’s expression not being regulated by the other (Sreenath 
et al., 1999; Jung et al., 2004b). Third, despite general concept 
as a transcription factor, HOXB13 may have a function as a 
non-DNA binding protein being a transcriptional repressor 
(Zappavigna et al., 1994; Catron et al., 1995; Schnabel 
& Abate-Shen, 1996). Several HOX proteins, including 
HOXB13, prevent acetyltransferase function of CBP/p300 
coactivators by physical interaction (Shen et al., 2001; Shen 
et al., 2004). Moreover, HOX proteins do not contain typical 
hormone receptor binding motifs (Schnabel & Abate-Shen, 
1996; Zeltser et al., 1996). Experimental focus of this report 
was on regulatory mechanism of HOXB13 in AR signals 
while proposed hypothesis is not comprehensively tested yet. 
Further studies should include deletion and/or mutagenesis 
analyses to delineate interacting domains of HOXB13 and 
AR, elucidation of detailed association of HOXB13 with many 
nuclear receptor coactivators, and finally biological effects of 
minimal AR-interacting portion of HOXB13 through in vivo 
studies. Outcome of this long-term experiments will provide 
unique mechanism in androgen-mediated AR signaling 
pathway and HOXB13’s clinical role in development of 
hormone refractory PCa.
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